生物化学与生物物理进展2024,Vol.51Issue(4) :850-857.DOI:10.16476/j.pibb.2023.0267

前蛋白转换酶枯草溶菌素9抑制剂降低脂蛋白(a)作用的机制

The Mechanisms of PCSK9 Inhibitor Reducing Lipoprotein(a)

薛宇 刘海伟 李洋
生物化学与生物物理进展2024,Vol.51Issue(4) :850-857.DOI:10.16476/j.pibb.2023.0267

前蛋白转换酶枯草溶菌素9抑制剂降低脂蛋白(a)作用的机制

The Mechanisms of PCSK9 Inhibitor Reducing Lipoprotein(a)

薛宇 1刘海伟 2李洋2
扫码查看

作者信息

  • 1. 北部战区总医院心血管内科,沈阳 110016;中国医科大学北部战区总医院研究生培养基地,沈阳 110016
  • 2. 北部战区总医院心血管内科,沈阳 110016
  • 折叠

摘要

脂蛋白(a)(lipoprotein(a),Lp(a))在结构上与低密度脂蛋白相似,是动脉粥样硬化性心血管疾病发病的独立危险因素和潜在的治疗靶点.前蛋白转换酶枯草溶菌素9(proprotein convertase subtilisin/kexin type 9,PCSK9)抑制剂可有效降低Lp(a)的循环水平并减少心血管事件风险.本文综合近年来的相关研究,阐述PCSK9抑制剂减少Lp(a)合成和促进其降解的相关机制,分析该领域所面临的挑战和未来的发展方向.

Abstract

Lipoprotein(a)(Lp(a))is a complex circulating lipoprotein,and increasing evidence has demonstrated its role as a risk factor for atherosclerotic cardiovascular disease and as a possible therapeutic target.Proprotein converting enzyme proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitor significantly decreases the circulating level of Lp(a)and reduces the risk of cardiovascular events.Based on the research results in recent years,this review will systematically summarize the relevant mechanisms of PCSK9 inhibitor reducing Lp(a)synthesis and promoting its degradation.The mechanisms are influenced by whether statins used in combination and baseline levels of Lp(a).PCSK9 inhibitors decrease Lp(a)levels mainly by reducing Lp(a)synthesis.However,the importance of low-density lipoprotein receptor(LDLR)mediated enhancing Lp(a)degradation gradually increases when the LDL level decreases.Meanwhile,many other receptor pathways may also exist,including very low-density lipoprotein(VLDL)receptor,LDL receptor-related protein 1,CD36,toll-like receptor 2,scavenger receptor B1 and plasminogen receptor.At present,further studies are still needed to explore the mechanisms by which PCSK9 inhibitors reduce Lp(a)level,such as inhibition of Lp(a)synthesis and intracellular assembly,and LDLR-mediated Lp(a)degradation.In addition,whether the reduction of Lp(a)level by PCSK9 inhibitor is related to age,gender and race and whether the dose-effect relationship of reducing Lp(a)is influenced by background lipid level,all of which require in-depth exploration.In short,the cellular and molecular mechanisms underlying the regulation of Lp(a)synthesis and degradation is not completely clear.It is worth carrying out relevant research to provide a theoretical basis for better clinical application of such drugs.

关键词

脂蛋白(a)/前蛋白转换酶枯草溶菌素9抑制剂/动脉粥样硬化性心血管疾病/低密度脂蛋白受体

Key words

lipoprotein(a)/PCSK9 inhibitor/atherosclerotic cardiovascular disease/LDL receptor

引用本文复制引用

基金项目

辽宁省自然科学基金(2022-KF-12-02)

沈阳市科技创新人才支持计划(RC220400)

出版年

2024
生物化学与生物物理进展
中国科学院生物物理研究所,中国生物物理学会

生物化学与生物物理进展

CSTPCD北大核心
影响因子:0.476
ISSN:1000-3282
参考文献量42
段落导航相关论文